Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 14/20 | 0.74 |
| ▸ | TACR1 | P25103 | 12/20 | 0.74 |
| ▸ | TACR3 | P29371 | 8/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | CCR5 | P51681 | 4/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699201 | 1.00 | TACR2 (0.74) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6699197 | 1.00 | TACR2 (0.74) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7086354 | 0.99 | TACR2 (0.73) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7086355 | 0.99 | TACR2 (0.73) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6448448 | 0.99 | TACR2 (0.73) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL31224123 | 0.99 | TACR2 (0.73) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6544542 | 0.90 | TACR2 (0.71) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6543127 | 0.90 | TACR2 (0.70) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6449071 | 0.90 | TACR2 (0.72) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7311062 | 0.88 | TACR2 (0.64) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2003-04-17 | — | — | US | claimed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2001-11-01 | — | — | US | claimed |
| WO-1998011090-A2 | 3-ALKYL-3-PHENYL-PIPERIDINES | WARNER-LAMBERT COMPANY (US) | 1998-03-19 | — | — | WO | claimed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | disclosed |
| US-6602886-B2 | 3-alkyl-3-phenyl-piperidines | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2003-04-17 | — | — | US | disclosed |
| US-6433178-B2 | ALKYL PYRIMIDINES SUBSTITUTED PIPERIDINE DERIVATIVES ARE USED AS TACHYKININ ANTAGONSIT, USEFUL IN THE TREATMENT OF PAIN, DEPRESSION, ANXIETY, PANIC, SCHIZOPHRENIA, NEURALGIA, ADDICTION DISORDER, INFLAMMATION, AND NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2002-08-13 | — | — | US | disclosed |
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2001-11-01 | — | — | US | disclosed |
| US-6040316-A | TACHYKININ ANTAGONISTS TREATING PAIN, DEPRESSION, ANXIETY, PANIC, SCHIZOPHRENIA, NEURALGIA, ADDICTION DISORDERS, INFLAMMATORY DISEASES, GASTROINTESTINAL DISORDERS, VASCULAR DISORDERS, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1998011090-A2 | 3-ALKYL-3-PHENYL-PIPERIDINES | WARNER-LAMBERT COMPANY (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR2 7/4885TACR1 1/4885TACR3 86/4885 |
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | TAC3, KCNK3, ACKR3 | TACR2 10/4885TACR1 21/4885TACR3 22/4885 |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | TAC3, KCNK3, ACKR3 | TACR2 10/4885TACR1 21/4885TACR3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.